BNGO Bionano Genomics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BNGO

Price (delayed)

$1.27

Market cap

$14.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.37

Enterprise value

$17.9M

?
Relative Growth: Rel. Growth: 42
Relative Strength: Rel. Strength: 14
Relative Valuation: Rel. Valuation: 36
Relative Profitability: Rel. Profitability: 29

Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for ...

Highlights
The EPS has soared by 92% YoY and by 10% QoQ
Bionano Genomics's debt has decreased by 8% YoY
The company's net income has surged by 62% YoY but it fell by 20% QoQ
BNGO's quick ratio is up by 11% year-on-year but it is down by 10% since the previous quarter
BNGO's equity is down by 22% YoY and by 16% from the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://bionanogenomics.com
Peers: RVTY QTRX PRPO MTD

Key stats

What are the main financial stats of BNGO

BNGO stock price

How has the Bionano Genomics stock price performed over time
Intraday
-2.31%
1 week
1.6%
1 month
2.42%
1 year
-65.68%
YTD
-16.99%
QTD
8.55%

Financial performance

How have Bionano Genomics's revenue and profit performed over time
Revenue
$28.74M
Gross profit
$13.5M
Operating income
-$32.77M
Net income
-$31.6M
Gross margin
47%
Net margin
-109.9%
Bionano Genomics's net margin has soared by 63% YoY but it has decreased by 19% from the previous quarter
The company's net income has surged by 62% YoY but it fell by 20% QoQ
The operating margin has surged by 60% year-on-year and by 2.5% since the previous quarter
BNGO's operating income has soared by 60% YoY

Price vs fundamentals

How does BNGO's price correlate with its fundamentals

Growth

What is Bionano Genomics's growth rate over time

Valuation

What is Bionano Genomics stock price valuation
P/E
N/A
P/B
0.38
P/S
0.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.62
The EPS has soared by 92% YoY and by 10% QoQ
BNGO's price to book (P/B) is 73% lower than its 5-year quarterly average of 1.4 but 27% higher than its last 4 quarters average of 0.3
BNGO's equity is down by 22% YoY and by 16% from the previous quarter
The P/S is 98% below the 5-year quarterly average of 20.8 but 25% above the last 4 quarters average of 0.4

Efficiency

How efficient is Bionano Genomics business performance
The ROS has soared by 63% YoY but it has decreased by 19% QoQ
Bionano Genomics's ROIC has soared by 62% YoY but it has decreased by 27% from the previous quarter
Bionano Genomics's return on equity has surged by 55% YoY but it has decreased by 27% QoQ
Bionano Genomics's return on assets has surged by 52% YoY but it has decreased by 25% QoQ

Dividends

What is BNGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BNGO.

Financial health

How did Bionano Genomics financials performed over time
BNGO's total assets is 137% greater than its total liabilities
BNGO's total assets is down by 17% year-on-year and by 12% since the previous quarter
BNGO's quick ratio is up by 11% year-on-year but it is down by 10% since the previous quarter
Bionano Genomics's debt is 55% less than its equity
BNGO's equity is down by 22% YoY and by 16% from the previous quarter
The debt to equity rose by 18% since the previous quarter and by 18% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.